Trial Evaluating Ambulatory Therapy of Travelers’ Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide
暂无分享,去创建一个
Akira A Shishido | J. Maguire | R. Deiss | Jason B Blitz | C. Duplessis | E. Hutley | D. Tribble | R. Maves | T. Burgess | M. Riddle | P. Connor | Jamie A Fraser | C. Porter | B. Swierczewski | B. Danboise | M. Simons | C. Hulseberg | T. Lalani | R. Gutierrez | M. Adam | E. Akorli | R. Armstrong | Lucy Ashford-Brown | Jaime Alvarado | R. Avilés | C. Ayres | Timothy P Ballard | L. Barry | M. Bavaro | Catherine M. Berjohn | R. Bjoraker | P. Blenkinsop | Jeromy Boucher | D. Burns | Jenna Burns | S. Butler | Anthony Cancio | A. Cardile | Tarah Carnes | Fongkuei Cheng | K. Clay | David O. Cook | C. Duffield | R. Dyer | Aaron Farmer | Robert P Gormley | A. Hazlerigg | J. Hemmings | N. Hill | Emily Hollis | J. Hutter | Alshia Johnson | Paul Kartchner | Fred Kency | K. Latimer | J. Lentaigne | A. Letizia | Jennifer Masel | A. Miura | L. Moore | O. Oladipo | Shane B. Patterson | Mark Pence | A. Proffitt | J. Rimmer | Benjamin Rodriguez | Carlo Rossi | C. Royston | Melanie Sanders | Karen J. Santiago | T. Scorer | A. Self | Mildred Sitonik | D. Snyder | Garrick Stride | H. Tilley | Matthew R Timlin | Melanie Trado | Detonya Tulsie | L. Viswanathan | T. Warkentien | J. Wedgwood | S. White | Jamie A. Fraser | C. Berjohn | Akira A. Shishido | Jack N Hutter | M. Timlin | Timothy Ballard
[1] J. Vila. New molecular diagnostic tools in traveller's diarrhea. , 2017, Journal of travel medicine.
[2] H. Dupont,et al. ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults , 2016, The American Journal of Gastroenterology.
[3] A. Zinsmeister,et al. Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome , 2016, Clinical and Translational Gastroenterology.
[4] L. Wieler,et al. High carriage rate of ESBL-producing Enterobacteriaceae at presentation and follow-up among travellers with gastrointestinal complaints returning from India and Southeast Asia. , 2016, Journal of travel medicine.
[5] A. Kantele,et al. Increased Risk for ESBL-Producing Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers’ Diarrhea , 2016, Emerging infectious diseases.
[6] P. V. van Genderen,et al. International travel and acquisition of multidrug-resistant Enterobacteriaceae: a systematic review. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[7] M. Esposito‐Farèse,et al. High Rate of Acquisition but Short Duration of Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] H. Dupont. Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. , 2015, Mayo Clinic proceedings.
[9] J. Ollgren,et al. Antimicrobials Increase Travelers' Risk of Colonization by Extended-Spectrum Betalactamase-Producing Enterobacteriaceae , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] H. Dupont,et al. Traveler's diarrhea: a clinical review. , 2015, JAMA.
[11] Lars L. Andersen,et al. Interventions to increase physical activity for people with congenital heart disease , 2014 .
[12] Caroline A. Schrodt,et al. Rifaximin-Mediated Changes to the Epithelial Cell Proteome: 2-D Gel Analysis , 2013, PloS one.
[13] K. Garey,et al. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections , 2010, Expert review of anti-infective therapy.
[14] J. Klena,et al. Design and validation of a multiplex polymerase chain reaction for the identification of enterotoxigenic Escherichia coli and associated colonization factor antigens. , 2010, Diagnostic microbiology and infectious disease.
[15] H. Dupont,et al. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. , 2009, The American journal of tropical medicine and hygiene.
[16] D. Tribble,et al. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] H. Dupont,et al. Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. , 2007, Journal of travel medicine.
[18] R. Frenck,et al. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] H. Dupont,et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[20] C. Mason,et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] D. Diemert. Prevention and Self-Treatment of Traveler's Diarrhea , 2006, Clinical Microbiology Reviews.
[22] H. Dupont,et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. , 2006, The American journal of tropical medicine and hygiene.
[23] D. Tribble,et al. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. , 2006, The American journal of tropical medicine and hygiene.
[24] H. Dupont,et al. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] D. Shlim. Update in traveler's diarrhea. , 2005, Infectious disease clinics of North America.
[26] Khanh Nguyen Gia,et al. Detection and Characterization of Diarrheagenic Escherichia coli from Young Children in Hanoi, Vietnam , 2005, Journal of Clinical Microbiology.
[27] H. Dupont,et al. Empirical antimicrobial therapy for traveler's diarrhea. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] G. de Bruyn,et al. Antibiotic treatment for travellers' diarrhoea. , 2000, The Cochrane database of systematic reviews.
[29] H. Dupont,et al. Single Dose Ofloxacin plus Loperamide Compared with Single Dose or Three Days of Ofloxacin in the Treatment of Traveler's Diarrhea. , 1997, Journal of travel medicine.
[30] D. Lüscher,et al. Detection of shigellae, enteroinvasive and enterotoxigenic Escherichia coli using the polymerase chain reaction (PCR) in patients returning from tropical countries. , 1994, Molecular and cellular probes.
[31] M. Cohen,et al. Traveler's diarrhea. , 1993, American family physician.
[32] L F Burmeister,et al. Proving the Null Hypothesis , 1992, Infection Control & Hospital Epidemiology.
[33] H. Dupont,et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. , 1990, The American journal of medicine.
[34] H. Dupont,et al. Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea. , 1986, JAMA.
[35] W C Blackwelder,et al. "Proving the null hypothesis" in clinical trials. , 1981, Controlled clinical trials.
[36] H. Dupont. Travellers’ Diarrhoea: Contemporary Approaches to Therapy and Prevention , 2012, Drugs.
[37] F. Raffi,et al. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.